How microRNAs influence both hereditary and inflammatory-mediated colon cancers

Cancer Genetics

Volumn 206, Issue 9-10, 2013, Pages 309-316

  Hutchison, Jennifer ^a   Cohen, Zoe ^b   Onyeagucha, Benjamin C ^b   Funk, Janet ^b   Nelson, Mark A ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Crohn's disease; FAP; HNPCC; MicroRNA; Ulcerative colitis

Indexed keywords

APC PROTEIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EXPORTIN 5; LET 7A; MICRORNA; MICRORNA 100; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 200; MICRORNA 26A; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; RNA INDUCED SILENCING COMPLEX; STAPHYLOCOCCAL NUCLEASE TUDOR DOMAIN CONTAINING 1; UNCLASSIFIED DRUG;

ADENOMATOUS POLYPOSIS COLI GENE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHRONIC INFLAMMATION; COLON CANCER; CROHN DISEASE; DISEASE ASSOCIATION; EXPORTIN 5 GENE; FAMILIAL COLON POLYPOSIS; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

CROHN'S DISEASE; FAP; HNPCC; MICRORNA; ULCERATIVE COLITIS;

ADENOMATOUS POLYPOSIS COLI; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CROHN DISEASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MODELS, GENETIC; RISK FACTORS;

EID: 84888437742     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2013.06.005     Document Type: Review

References (75)

1. Heavey P.M., McKenna D., Rowland I.R. Colorectal cancer and the relationship between genes and the environment. Nutrition and Cancer-an International Journal 2004, 48(2):124-141.
2. Terzic J., et al. Inflammation and colon cancer. Gastroenterology 2010, 138(6):2101-2119.
3. Schetter A.J., Harris C.C. Alterations of microRNAs contribute to colon carcinogenesis. Seminars in Oncology 2011, 38(6):734-742.
4. Chan D.S.M., et al. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. Plos One 2011, 6(6).
5. Doubeni C.A., et al. Socioeconomic status and the risk of colorectal cancer an analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study. Cancer 2012, 118(14):3636-3644.
6. Sonja H., Damjan G. MicroRNAs as novel biomarkers in colorectal cancer. Frontiers in Genetics 2012, 3(180):1-9.
7. Society, A.C., Colorectal Cancer Facts and Figures2011-2013, M. Rick Alteri, etal., Editors. 2011, American Cancer Society: Atlanta GA.
8. Kanaan Z., et al. Plasma miR-21 a potential diagnostic marker of colorectal cancer. Annals of Surgery 2012, 256(3):544-551.
9. Bandi P., et al. Trends in colorectal cancer screening with home-based fecal occult blood tests in adults ages 50 to 64 years, 2000-2008. Cancer 2012, 118(20):5092-5099.
10. Smith R.A., Cokkinides V., Brawley O.W. Cancer screening in the United States, 2012 A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-a Cancer Journal for Clinicians 2012, 62(2):129-142.
11. Burch J.A., et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. Journal of Medical Screening 2007, 14(3):132-137.
12. Klabunde C.N., et al. Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiology Biomarkers & Prevention 2011, 20(8):1611-1621.
13. Society A.C. Cancer Facts and Figures2012 2012, American Cancer Society, Atlanta GA.
14. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nature Reviews Molecular Cell Biology 2005, 6(5):376-385.
15. Liu C., et al. CLIP-based prediction of mammalian microRNA binding sites. Nucleic Acids Res 2013.
16. Cowland J.B., Hother C., Gronwaek K. MicroRNAs and cancer. Apmis 2007, 115(10):1090-1106.
17. Ciafre S.A., Galardi S. MicroRNAs and RNA-binding proteins: A complex network of interactions and reciprocal regulations in cancer. RNA Biol 2013, 10(6).
18. Lu J., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838.
19. Pavicic W., et al. altered methylation at microRNA-associated CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)-based approach. Molecular Medicine 2011, 17(7-8):726-735.
20. Akao Y., Nakagawa Y., Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncology Reports 2006, 16(4):845-850.
21. Mattiske S., et al. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiology Biomarkers & Prevention 2012, 21(8):1236-1243.
22. Pu J., et al. Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of MiR-155. Biochemical and Biophysical Research Communications 2012, 428(2):210-215.
23. Miaomiao Y., et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small celllung cancer. European Journal of Cancer 2012, 49(3):604-615.
24. Akao Y., Nakagawa Y., Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biological & Pharmaceutical Bulletin 2006, 29(5):903-906.
25. Guo C., et al. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes & Cancer 2008, 47(11):939-946.
26. Saito Y., et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9(6):435-443.
27. Nagel R., et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Research 2008, 68(14):5795-5802.
28. Hu M., et al. MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Digestive Diseases and Sciences 2010, 55(8):2365-2372.
29. Song B., et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009, 28(46):4065-4074.
30. Asangani I.A., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27(15):2128-2136.
31. Schimanski C.C., et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World Journal of Gastroenterology 2009, 15(17):2089-2096.
32. Burk U., et al. Areciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. Embo Reports 2008, 9(6):582-589.
33. Ng E.K.O., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58(10):1375-1381.
34. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nature Medicine 2004, 10(8):789-799.
35. Jasperson K.W., et al. Hereditary and familial colon cancer. Gastroenterology 2010, 138(6):2044-2058.
36. Itzkowitz S.H., Yio X.Y. Inflammation and cancer - IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. American Journal of Physiology-Gastrointestinal and Liver Physiology 2004, 287(1):G7-G17.
37. Balaguer F., et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clinical Cancer Research 2011, 17(19):6239-6249.
38. Valeri N., et al. Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(15):6982-6987.
39. Nishisho I., et al. Mutations of chromosome-5q21 genes in FAP and colorectal-cancer patients. Science 1991, 253(5020):665-669.
40. Nakamura Y., et al. Mutations of the APC (adenomatous-polyposis-coli) gene in FAP (familial-polyposis-coli) patients and in sporadic colorectal tumors. Tohoku Journal of Experimental Medicine 1992, 168(2):141-147.
41. Tighe A., Johnson V.L., Taylor S.S. Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. Journal of Cell Science 2004, 117(26):6339-6353.
42. Shi C., Washington K. Molecular testing in colorectal cancer diagnosis of lynch syndrome and personalized cancer medicine. American Journal of Clinical Pathology 2012, 137(6):847-859.
43. Bos J.L., et al. Prevalence of ras gene-mutations in human colorectal cancers. Nature 1987, 327(6120):293-297.
44. Chen X., et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009, 28(10):1385-1392.
45. Pichler M., et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. British Journal of Cancer 2012, 106(11):1826-1832.
46. Tsuchiya N., et al. SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis. Cancer Research 2007, 67(19):9568-9576.
47. Dalal S., Kwon J. The role of MicroRNA in inflammatory bowel disease. Gastroenterology & Hepatology 2010, 6(11):714-722.
48. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature Clinical Practice Gastroenterology & Hepatology 2006, 3(7):390-407.
49. Ordas I., et al. Ulcerative colitis. Lancet 2012, 380(9853):1606-1619.
50. Fasseu M., et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. Plos One 2010, 5(10):12.
51. Ye D., et al. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology 2011, 141(4):1323-1333.
52. Kohonen-Corish M.R.J., et al. Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumors. Cancer Research 2002, 62(7):2092-2097.
53. Tili E., et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(12):4908-4913.
54. Wu F., et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflammatory Bowel Diseases 2010, 16(10):1729-1738.
55. Wu F., et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008, 135(5):1624-1635.
56. Feng X., et al. Up-Regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IκBα. PLoS One 2012, 7(12):e52782.
57. Takagi T., et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. Journal of Gastroenterology and Hepatology 2010, 25:S129-S133.
58. Pekow J.R., et al. miR-143 and miR-145 are downregulated in ulcerative colitis: Putative regulators of inflammation and protooncogenes. Inflammatory Bowel Diseases 2012, 18(1):94-100.
59. Olaru A.V., et al. Dynamic changes in the expression of microRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflammatory Bowel Diseases 2011, 17(1):221-231.
60. Strillacci A., et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Experimental Cell Research 2009, 315(8):1439-1447.
61. Tanaka T., et al. AmicroRNA, miR-101a, controls mammary gland development by regulating cyclooxygenase-2 expression. Differentiation 2009, 77(2):181-187.
62. Ji Y., et al. MiRNA-26b regulates the expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells. Febs Letters 2010, 584(5):961-967.
63. Hsi L.C., Angerman-Stewart J., Eling T.E. Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level. Carcinogenesis 1999, 20(11):2045-2049.
64. Chandramouli A., et al. MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biology & Therapy 2012, 13(3):175-183.
65. Boni V., et al. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics Journal 2011, 11(6):429-436.
66. Landi D., et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008, 29(3):579-584.
67. Melo S.A., et al. Agenetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 2010, 18(4):303-315.
68. Zwiers A., et al. Cutting edge: a variant of the IL-23R gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production. Journal of Immunology 2012, 188(4):1573-1577.
69. Moore A.E., Young L.E., Dixon D.A. Acommon single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation. Oncogene 2012, 31(12):1592-1598.
70. Chen S.P., et al. Single nucleotide polymorphisms of the APC gene and colorectal cancer risk: a case-control study in Taiwan. Bmc Cancer 2006, 6.
71. Ma L., et al. Agenetic variant in miR-146a modifies colorectal cancer susceptibility in a Chinese population. Archives of Toxicology 2013, Epub ahead of print.
72. Boulard O., et al. Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. Journal of Experimental Medicine 2012, 209(7):1309-1324.
73. Mitchell P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(30):10513-10518.
74. Ruzzo A., et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 2012, 17(6):823-829.
75. Adam L., et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clinical Cancer Research 2009, 15(16):5060-5072.